未登录

C

Christina Esdar

merck kga a

H指数:21

被引数:1,439

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck

头颈部鳞状细胞癌的凋亡逃避和治疗抵抗

CANCER TREATMENT REVIEWS

IF10.5

2024-09-012

OAAI

Extended treatment with IAP inhibitor xevinapant post radiotherapy improves therapeutic efficacy and promotes antitumor immunity in preclinical models

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Compound library screening to identify modulators of alternative splicing in non-small cell lung cancer (NSCLC)

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line-Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)

CLINICAL CANCER RESEARCH

IF10.2

2023-05-245

OA

Identification of M4205-A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2023-02-026

PRE

Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck

CANCER TREATMENT REVIEWS

IF10.5

2023-02-019

OAAI

Translational PK/PD Modeling of Tumor Growth Inhibition and Target Inhibition to Support Dose Range Selection of the LMP7 Inhibitor M3258 in Relapsed/Refractory Multiple Myeloma

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2023-01-014

OAAI

MSC-1186, a Highly Selective Pan-SRPK Inhibitor Based on an Exceptionally Decorated Benzimidazole-Pyrimidine Core

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2022-12-144

PRE

Optimization of a Screening Hit toward M2912, an Oral Tankyrase Inhibitor with Antitumor Activity in Colorectal Cancer Models

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2021-07-132

PRE

Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i)

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2021-07-060

PREAI

FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response

EUROPEAN JOURNAL OF CANCER

IF7.1

2021-07-0130

OAAI

M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models

MOLECULAR CANCER THERAPEUTICS

IF5.5

2021-05-2721

OAAI

A novel monovalent FGFR1 antagonist: Preclinical safety profiles in rodents and non-human primates

TOXICOLOGY AND APPLIED PHARMACOLOGY

IF3.4

2020-11-014

OAAI

Unraveling mechanisms of resistance to tepotinib and future treatment options

CANCER RESEARCH

IF16.6

2020-08-152

PRE

M6123, a selective FGFR1 antagonist, demonstrates anti-tumor activity as monotherapy and in combination with chemotherapy in mesothelioma models

CANCER RESEARCH

IF16.6

2020-08-150

PRE

Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2019-08-0527

PREAI

M6123 is an ADCC-enhanced and selective monovalent antagonist of FGFR1 showing antitumor activity in preclinical lung cancer models

CANCER RESEARCH

IF16.6

2019-07-012

PRE

Discovery and profiling of M3258, a potent and selective LMP7 inhibitor demonstrating high efficacy in multiple myeloma models

CANCER RESEARCH

IF16.6

2019-07-017

PRE

First-time disclosure of M3258: A selective inhibitor of the immunoproteasome subunit LMP7 with potential for improved therapeutic utility in multiple myeloma compared to pan-proteasome inhibitors

CANCER RESEARCH

IF16.6

2019-07-019

PRE

A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors

SCIENTIFIC REPORTS

IF3.9

2019-01-1744

OAAI